These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15467893)

  • 1. Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia.
    Hayward CP
    Thromb Haemost; 2004 Oct; 92(4):674-5. PubMed ID: 15467893
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
    Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
    Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
    [No Abstract]   [Full Text] [Related]  

  • 3. Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia.
    Holmes MB; Kabbani S; Watkins MW; Battle RW; Schneider DJ
    Circulation; 2000 Feb; 101(8):938-9. PubMed ID: 10694535
    [No Abstract]   [Full Text] [Related]  

  • 4. Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy.
    Claeys LG; Berg W
    Eur J Vasc Endovasc Surg; 2003 Jan; 25(1):85-7. PubMed ID: 12525818
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
    Makoni SN
    Heart; 2001 Dec; 86(6):E18. PubMed ID: 11711483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-induced thrombocytopenia].
    Hangaishi A; Kurokawa M
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():465-9. PubMed ID: 18074583
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal delayed thrombocytopenia following abciximab therapy.
    McCorry RB; Johnston P
    J Invasive Cardiol; 2006 Jun; 18(6):E173-4. PubMed ID: 16775895
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed immunologic thrombocytopenia induced by abciximab.
    Nurden P; Clofent-Sanchez G; Jais C; Bermejo E; Leroux L; Coste P; Nurden AT
    Thromb Haemost; 2004 Oct; 92(4):820-8. PubMed ID: 15467914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Images in cardiovascular medicine: pseudothrombocytopenia after abciximab (ReoPro) treatment.
    Moll S; Poepping I; Hauck S; Gulba D; Dietz R
    Circulation; 1999 Sep; 100(13):1460. PubMed ID: 10500049
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets.
    Curtis BR; Swyers J; Divgi A; McFarland JG; Aster RH
    Blood; 2002 Mar; 99(6):2054-9. PubMed ID: 11877279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy.
    Reddy MS; Carmody TJ; Kereiakes DJ
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):486-8. PubMed ID: 11285605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug.
    Curtis BR; Divgi A; Garritty M; Aster RH
    J Thromb Haemost; 2004 Jun; 2(6):985-92. PubMed ID: 15140135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro).
    Sharma S; Bhambi B; Nyitray W; Sharma G; Shambaugh S; Antonescu A; Shukla P; Denny E
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):21-4. PubMed ID: 12000974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies.
    Lown JA; Hughes AS; Cannell P
    Heart; 2004 Sep; 90(9):e55. PubMed ID: 15310724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
    Rasti M; Blostein M
    Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration.
    Webb GJ; Swinburn JM; Grech H
    Platelets; 2011; 22(4):302-4. PubMed ID: 21526887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe thrombocytopenia after an infusion of abciximab.
    Rubio A; González C; Majado MJ; Salido E; García-Candel F; González-Carrillo J
    Haematologica; 2001 Mar; 86(3):E05. PubMed ID: 11255292
    [No Abstract]   [Full Text] [Related]  

  • 18. Understanding the complexity of abciximab-related thrombocytopenia.
    De Caterina R; Zimarino M
    Thromb Haemost; 2010 Mar; 103(3):484-6. PubMed ID: 20135055
    [No Abstract]   [Full Text] [Related]  

  • 19. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy.
    Jenkins LA; Lau S; Crawford M; Keung YK
    Circulation; 1998 Mar; 97(12):1214-5. PubMed ID: 9537353
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombocytopenia associated with c7E3 Fab (abciximab).
    Schell DA; Ganti AK; Levitt R; Potti A
    Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.